- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Peptone Appoints New Leaders to C-Suite
The company announced new hires for its chief scientific officer, chief business officer, and other leadership roles.
Peptone, a biophysics company designing novel therapeutics against IDPs, announced multiple new hires for its leadership team.
In a press release, the company announced that Patrik Foerch, PhD, has been appointed as chief scientific officer. David Lowe, PhD, has also been appointed to the role of senior vice president of protein therapeutics, while Benjamin Owens, PhD, will move to the role of chief business officer from his previous role as chief strategy officer.
Peptone’s CEO, Kamil Tamiola, PhD, said in a press release, “The expansion of Peptone's executive team with deep drug discovery and development expertise comes at an important moment in time for the company and will enable us to capitalize on our proprietary computational and experimental approaches, accelerating the company's internal drug discovery programs and external partnerships. We are thrilled to welcome Patrik and David to the organization and grateful for Benjamin and Andrew's leadership and contributions in this important new phase of the company's development and growth."
Source
(Sept. 28, 2023); Peptone; Peptone Expands Leadership Team with Key Executive Hires; https://www.prnewswire.com/news-releases/peptone-expands-leadership-team-with-key-executive-hires-301941099.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
